Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Metall Zug AG ( (CH:METN) ) has issued an update.
Metall Zug AG reported a challenging first half of 2025, with net sales significantly declining to CHF 94.2 million, primarily due to the divestment of Belimed and negative currency effects. Despite these challenges, the company is optimistic about future growth, driven by new product launches from its Haag-Streit unit, including the world-first Elara 900 slit lamp. The ongoing integration of SteelcoBelimed is on track, with initial synergies expected to improve operational efficiency. The company is also undergoing a leadership change at Haag-Streit, with Thomas Lenzen taking over as CEO to continue driving international growth and innovation.
The most recent analyst rating on (CH:METN) stock is a Hold with a CHF1082.00 price target. To see the full list of analyst forecasts on Metall Zug AG stock, see the CH:METN Stock Forecast page.
More about Metall Zug AG
Metall Zug AG operates in the medical devices industry, focusing on innovative products and solutions. The company is known for its high-quality surgical microscopes and digital imaging technologies, primarily serving ophthalmologists and optometrists.
YTD Price Performance: -9.83%
Average Trading Volume: 246
Technical Sentiment Signal: Strong Sell
Current Market Cap: CHF448.3M
For a thorough assessment of METN stock, go to TipRanks’ Stock Analysis page.